Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has decided to participate in a rights offering of its U.S. subsidiary (Samsung Biologics America) to acquire 350,000 new shares for approximately KRW 524.9B in cash.
📊 [Key Disclosure Details & Financial Summary]
- Target Company:
- Company Name & Nationality: Samsung Biologics America, Inc. (USA)
- CEO: Yong-Hwan Jin
- Capital Stock: KRW 11,914,000,000
- Relationship: 100% owned subsidiary (Affiliate)
- Total Shares Issued: 10,000 shares
- Core Business: Biopharmaceutical development and other business support services
- Acquisition Details & Amount:
- Number of Shares Acquired: 350,000 common shares
- Acquisition Amount: KRW 524.895B / KRW 524,895,000,000 (USD 350,000,000, applied FX rate of USD/KRW 1,499.70 as of March 20, 2026)
- Financial Ratios: 7.04% of Total Equity (KRW 7.45T) and 4.75% of Total Assets (KRW 11.06T) as of FY2025 consolidated balance sheet
- Post-Acquisition Ownership & Purpose:
- Post-Acquisition Ownership & Stake: 360,000 shares (100% stake)
- Acquisition Method: Participation in shareholder-directed rights offering (Cash acquisition, USD 1,000 per share)
- Purpose: Funding the subsidiary’s acquisition of securities in another corporation (acquisition of Human Genome Sciences in Rockville, U.S.) and covering operating expenses
- Scheduled Acquisition Date: 2026-03-27
- Board Resolution & Key Terms:
- Board Resolution Date: 2026-03-20 (4 outside directors attended, 0 absent)
- Backdoor Listing & Put Options: Not Applicable / No
- Other Notes: Schedules and details are subject to change during implementation.
- Target Company Financial Summary (As of FY2025):
- Total Assets: KRW 18,361,304,615
- Total Liabilities: KRW 3,044,015,112
- Total Equity: KRW 15,317,289,503
- Capital Stock: KRW 11,914,000,000
- Revenue: KRW 13,667,584,631
- Net Income: KRW 695,990,849
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Capital Payment Completion for Rights Offering Participation
This filing details the decision to inject capital into a 100% owned subsidiary to support its acquisition of a U.S. manufacturing facility and cover working capital. Verifying whether the capital payment and share acquisition are completed as planned on the scheduled acquisition date (March 27, 2026) is important for confirming the parent company’s capital execution and the subsidiary’s transaction progress. Details can be verified in upcoming periodic reports and subsequent disclosures.
📢 Disclaimer & Source Notice
Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).
Investment Risk Disclaimer: This content is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest entirely with the investor.
Contact: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.
